ID: ALA3265291

Max Phase: Preclinical

Molecular Formula: C18H14BrNO5S2

Molecular Weight: 468.35

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)CSc1cc(NS(=O)(=O)c2cccc(Br)c2)c2ccccc2c1O

Standard InChI:  InChI=1S/C18H14BrNO5S2/c19-11-4-3-5-12(8-11)27(24,25)20-15-9-16(26-10-17(21)22)18(23)14-7-2-1-6-13(14)15/h1-9,20,23H,10H2,(H,21,22)

Standard InChI Key:  QRNTXTIRONJKOT-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 468.35

Molecular Weight (Monoisotopic): 466.9497

AlogP: 4.29

#Rotatable Bonds: 6

Polar Surface Area: 103.70

Molecular Species: ACID

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.27

CX Basic pKa:

CX LogP: 3.71

CX LogD: 0.06

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.37

Np Likeness Score: -1.38

References

1. Abulwerdi FA, Liao C, Mady AS, Gavin J, Shen C, Cierpicki T, Stuckey JA, Showalter HD, Nikolovska-Coleska Z..  (2014)  3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.,  57  (10): [PMID:24749893] [10.1021/jm500010b]

2. Negi A, Murphy PV..  (2021)  Development of Mcl-1 inhibitors for cancer therapy.,  210  [PMID:33333396] [10.1016/j.ejmech.2020.113038]

Source

Source(1):

• Scientific Literature